What is changing in the rules, what it means for your product, your municipality or your project, and who here handles it. In English and Portuguese.
Our monitoring reports record the changes to cosmetics rules in a given period, and we publish one each month. Each one is a dated publication: it reflects the rules on the date it was published and is not updated afterwards. For what applies today, read the latest briefings or ask us.
Ingredient: THIOMERSAL AND PHENYLMERCURIC SALTS
Date of publication: 2 February 2026
The SCCS has concluded that Thiomersal and Phenylmercuric salts are not safe as preservatives at current concentrations permitted in cosmetic products.
Ingredient: SALICYLIC ACID
Date of publication: 14 January 2026
The SCCS has accepted a mandate to assess the safety of the aggregate exposure to Salicylic Acid.
Ingredient: BASIC BROWN 16
Date of publication: 2 February 2026
The SCCS has concluded that Basic Brown 16 (C009) cannot be considered safe for use in non-oxidative hair dye formulations due to mutagenicity concerns.
Ingredient: BASIC BLUE 99
Date of publication: 2 February 2026
The SCCS has concluded that Basic Blue 99 (C059) is not safe for use in non-oxidative hair dye formulations at 1% due to genotoxicity concerns.
Ingredient: PROSTAGLANDIN ANALOGUES - MDN, IPCP and DDDE
Date of publication: 2 February 2026
The SCCS has concluded that Methylamido-Dihydro-Noralfaprostal, Isopropyl Cloprostenate and Dechloro Dihydroxy Difluoro Ethylcloprostenolamide are not safe for use in eyelash and eyebrow cosmetic products.
Ingredient: SILVER
Date of publication: 26 March 2026
The SCCS has concluded that Silver is safe when used up to a maximum concentration of 0.2% in rinse-off products, 0.3% in leave-on products, 0.2% in oral hygiene products, 0.3% in nail products and 0.05% in mouthwash for children.
Ingredient: BUTYLATED HYDROXYANISOLE (BHA)
Date of publication: 26 March 2026
The SCCS published final scientific advice on the safety of BHA in cosmetic products, considering it safe for use up to 0.07% in dermal leave-on and rinse-off cosmetic products.
Ingredient: CANNABIDIOL
Date of publication: 26 March 2026
The SCCS published final scientific advice on the safety of Cannabidiol in cosmetic products, considering it safe for use up to 0.19% in dermal and oral cosmetic products.
Ingredient: HELIOTROPIN
Date of publication: 15 April 2026
The SCCS has issued its preliminary opinion establishing safe use concentration limits for Heliotropin in cosmetic products, allowing its continued use as an ingredient in fine fragrance for adults, despite pending CMR 1B classification under CLP Regulation. The deadline for comments is 15 June 2026.
Ingredient: ACETOPHENONE
Date of publication: 30 April 2026
The SCCS has issued its preliminary opinion establishing safe use concentration limits for Acetophenone in cosmetic products, allowing its continued use as a constituent of Natural Complex Substances, despite pending CMR 1B classification under CLP Regulation. The deadline for comments is 6 July 2026.
Ingredient: CYCLAMEN ALDEHYDE
Date of publication: 8 June 2026
The Scientific Committee on Consumer Safety (SCCS) has accepted a mandate to assess the safety of Cyclamen Aldehyde, following potential classification as a reproductive toxicant under the CLP Regulation.
Topic: OMNIBUS ACT IX - COSMETICS REGULATION
Date of publication: 28 July 2026
The European Commission notified the WTO about the draft Omnibus Act IX, proposing amendments to Annexes II, III, and V of the EU Cosmetics Regulation.
Topic: NEW RESTRICTIONS ON COSMETIC INGREDIENTS
Date of publication: 13 January 2026
The European Commission published Commission Regulation (EU) 2026/78, which brings new restrictions on several cosmetic ingredients that were classified as Carcinogenic, Mutagenic or Toxic for Reproduction (CMR).
Ingredient: TALC
Date of publication: January 2026
The United Kingdom (UK) Health and Safety Executive (HSE) has published a technical report concluding that Talc does not warrant carcinogenicity classification, diverging from ECHA's Risk Assessment Committee (RAC) opinion supporting Category 1B classification.
Four EUDAMED modules have been mandatory since 28 May 2026. Devices already on the market have until 27 November 2026. Who registers what, and what changed in Portugal.
From 25 February 2027, notified bodies under the MDR and IVDR must quote on defined information, keep to maximum timelines and publish their performance. What it changes for manufacturers.
Whether software is a medical device depends on what you say it is for, not on the code. The qualification test under the MDR and IVDR, updated for 2025 guidance.
Clinical data from an equivalent device can support your clinical evaluation, but the MDR sets a higher bar than the Directives did. The three characteristics, data access, and documentation.
One email when an area publishes, in the language you choose. Nothing else.
